UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
____________________________________________________________
Date of Report (Date of earliest event reported): November 12, 2015
MEDOVEX CORP.
(Exact Name of Registrant as Specified in Charter)
|
Nevada
|
001-36763
|
46-3312262
|
||
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
||
|
3279 Hardee Avenue
Atlanta, Georgia
|
30341
|
|||
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (844) 633-6839
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d 2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.07. Submission of Matters to a Vote of Security Holders.
On November 10, 2015, Medovex Corp. (the “Corporation”) held its Annual Meeting of Stockholders (the “Annual Meeting”) at which the Corporation’s stockholders approved four proposals (the “Proposals”) described more fully below. The Proposals are disclosed in the consent solicitation on Schedule 14A filed by the Corporation with the Securities and Exchange Commission (the “Commission”) on September 30, 2015 (the “Proxy”).
The Proposals approved at the Annual Meeting are as follows:
Proposal 1
All of the ten (10) nominees for director were elected to serve until the next Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director’s earlier resignation or removal. The result of the votes to elect the ten (10) directors was as follows:
|
Directors
|
For
|
Withheld
|
Abstain
|
Not Voted
|
|||||
|
Steve Gorlin
|
4,999,821
|
17,886
|
11,456
|
685,221
|
|||||
|
Clyde A. Hennies
|
4,963,185
|
54,522
|
11,456
|
685,221
|
|||||
|
James R. Andrews
|
4,999,821
|
17,886
|
11,456
|
685,221
|
|||||
|
Scott M.W. Haufe
|
5,010,997
|
6,710
|
11,456
|
685,221
|
|||||
|
Thomas E. Hills
|
4,963,407
|
54,300
|
11,456
|
685,221
|
|||||
|
Randal R. Betz
|
4,999,997
|
17,710
|
11,456
|
685,221
|
|||||
|
John C. Thomas, Jr.
|
5,010,821
|
6,886
|
11,456
|
685,221
|
|||||
|
John Blank
|
4,952,407
|
65,300
|
11,456
|
685,221
|
|||||
|
Larry Papasan
|
5,010,821
|
6,886
|
11,456
|
685,221
|
|||||
|
Jarrett Gorlin
|
4,999,997
|
17,710
|
11,456
|
685,221
|
Proposal 2
The retention of Frazier & Deeter LLC as independent registered public accounting firm for the fiscal year ending December 31, 2016 was approved by the stockholders by the votes set forth in the table below:
|
For
|
Against
|
Abstain
|
||
|
5,599,686
|
105,275
|
9,423
|
Proposal 3
The compensation of the Company’s named executive officers was approved, on an advisory basis, by the stockholders by the votes set forth in the table below:
|
For
|
Against
|
Abstain
|
Not Voted
|
|||
|
4,888,307
|
102,323
|
38,533
|
685,221
|
Proposal 4
The recommendation of a three year frequency with which the Company should conduct future stockholder advisory votes on named executive officer compensation was approved by the stockholders by the votes set forth in the table below:
|
Three Years
|
Two Years
|
One Year
|
Abstain
|
Not Voted
|
||||
|
3,685,484
|
823,160
|
491,519
|
29,000
|
685,221
|
The foregoing description of the Proposals does not purport to be complete and is qualified in its entirety by reference to the complete text of the Proxy.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
MEDOVEX CORP.
|
||
|
Date: November 12, 2015
|
By:
|
/s/ Jarrett Gorlin
Jarrett Gorlin
Chief Executive Officer
|